Search research articles
Contact Us
Filters
Showing results (101-110 of 162) with videos related to
Page
of 17
Sort By:
The Journal of Antimicrobial Chemotherapy
|
June 9, 2022
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study
Daniel K Nomah, Juliana Reyes-Urueña, Yesika Díaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 8, 2024
Risk of Tuberculosis After Achieving HIV Virological Suppression on Antiretroviral Therapy: A Danish Nationwide Prospective Cohort Study
Amrit Kaur Virdee, Fredrikke Christie Knudtzen, Josep M Llibre, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]
Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.
Plos One
|
December 3, 2014
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals
Marta Massanella, Dan Ouchi, Silvia Marfil, et al.
Eclinicalmedicine
|
August 12, 2022
Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study
Raquel Martin-Iguacel, Juliana Reyes-Urueña, Andreu Bruguera, et al.
The Journal of Antimicrobial Chemotherapy
|
May 17, 2013
Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy
Eugènia Negredo, Marta Massanella, Maria C Puertas, et al.
Frontiers in Immunology
|
June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study
Josep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|
January 13, 2024
The impact of the COVID-19 pandemic on healthcare services utilization among people living with HIV in Catalonia, Spain: A population-based cohort study
Yi-Hua Pan, Daniel K Nomah, Marcos Montoro-Fernandez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
The Journal of Antimicrobial Chemotherapy
|
May 1, 2013
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes
Lourdes Anta, José L Blanco, Josep M Llibre, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 162) with videos related to
Sort By:
Page
of 17
The Journal of Antimicrobial Chemotherapy
|
June 9, 2022
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study
Daniel K Nomah, Juliana Reyes-Urueña, Yesika Díaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 8, 2024
Risk of Tuberculosis After Achieving HIV Virological Suppression on Antiretroviral Therapy: A Danish Nationwide Prospective Cohort Study
Amrit Kaur Virdee, Fredrikke Christie Knudtzen, Josep M Llibre, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]
Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.
Plos One
|
December 3, 2014
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals
Marta Massanella, Dan Ouchi, Silvia Marfil, et al.
Eclinicalmedicine
|
August 12, 2022
Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study
Raquel Martin-Iguacel, Juliana Reyes-Urueña, Andreu Bruguera, et al.
The Journal of Antimicrobial Chemotherapy
|
May 17, 2013
Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy
Eugènia Negredo, Marta Massanella, Maria C Puertas, et al.
Frontiers in Immunology
|
June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study
Josep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|
January 13, 2024
The impact of the COVID-19 pandemic on healthcare services utilization among people living with HIV in Catalonia, Spain: A population-based cohort study
Yi-Hua Pan, Daniel K Nomah, Marcos Montoro-Fernandez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
The Journal of Antimicrobial Chemotherapy
|
May 1, 2013
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes
Lourdes Anta, José L Blanco, Josep M Llibre, et al.
Page
of 17